Our Team

Tracy Mazza Clemente serves as the Chief People Officer, holding prior positions as Head of Talent Acquisition and Global Head of HR. As the architect of the Agenus Talent Strategy, Tracy leads Agenus’ mission to discover and inspire the world’s greatest minds. By cultivating a workplace ethos of curiosity and ambition, Tracy empowers employees to harness their full potential and radically innovate on behalf of patients everywhere. Previously, Tracy led the US Scientific Talent Acquisition practice at Randstad. She holds a BA in Government and International Relations from Saint Mary’s College in Moraga, CA.

Alfred Dadson serves as Chief Manufacturing Officer in our Global Biologics Operations. Al is responsible for process development of our antibodies, vaccines, and cell therapies, from manufacturing through to commercialization. Previously, he was Vice President of Antibody Manufacturing Operations and Site Head of Agenus West, leading the team who developed a record number of eight antibody programs through to successful IND acceptance in under two years. Prior to joining Agenus, Al was Vice President of Manufacturing Operations and Facilities Engineering at XOMA. Al holds a patent on a state-of-the-art modular facility design and was named a lifetime member of Industry Leaders’ Who is Who by his peers.

Eric Humes serves as Agenus’ Chief Quality Officer (CQO). He heads our Global Quality Control laboratories (QCU), Product Development and Clinical Quality Assurance (QA), and Quality System Risk Management & Process Improvement. Eric’s leadership enables  our product development innovation and research to move with speed through a phase appropriate lifecycle focused on building quality into our products and research for the patients we serve. Eric joined Agenus as Vice President, Quality Systems, leading CMC and Clinical Research teams through successful completion of FDA inspections of balstilimab (AGEN2034) in 2021. Prior to joining Agenus, Eric was Executive Director, Quality Assurance at Medpace and Sr. Director QA at ICON Clinical Research, where Eric and his teams provided quality oversight, governance and inspection management in support of nine marketing applications in oncology, cardiovascular, orphan disease and biosimilars. Eric has served as a Director on the Society of Quality Assurance (SQA) Board of Directors, Chairman of SQA Education Committee, and Editorial Board of DIA Peach Initiative. Eric has a B.S. in Biochemistry and Applied Molecular Biology from University of Maryland.

Christine Klaskin serves as Agenus’ Vice President, Finance and Principal Financial Accounting Officer. She leads Agenus’ finance, accounting, corporate treasury functions, and is instrumental in negotiating our upfront licensing fees and distribution of revenue. Christine is Agenus’ public-facing financial representative and has helped the company make long-term financial decisions since its inception. Prior to joining Agenus, she served as an audit manager at Arthur Andersen. Christine received her Bachelor of Accountancy from George Washington University.

Dr. Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Steven played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.